SUNDAY, SEPTEMBER 25, 2016

Preclinical study shows DNA vaccine is effective against Ebola, Marburg viruses

Inovio Pharmaceuticals, Inc., announced on Tuesday that its SynCon DNA vaccine was effective against the Ebola and Marburg filoviruses in a recent preclinical challenge study.

The Ebola virus is one of the deadliest infections in the world, killing upwards of 90 percent of those who are infected. The virus starts with sudden influenza-like symptoms, which eventually escalate and begin to affect more parts of the body until multiple organs shut down.

The Marburg virus is similarly dangerous. It is hemorrhagic fever virus that can be weaponized as a biological weapon.

"This study again demonstrates the preventive potency and broad immune response that we consistently see in studies of our DNA portfolio of vaccines," Joseph Kim, Inovio president and CEO, said. "These immune response characteristics are the type considered necessary to achieve protection in humans."

There is currently no vaccine or therapy capable of combating the Ebola or Marburg viruses. The SynCon DNA vaccine may be able to prevent infection from these two viruses, both of which are highly contagious.

"These outstanding results support Inovio's active biodefense program, which has garnered multiple grants from the Department of Defense, Defense Threat Reduction Agency , National Institute of Allergy and Infectious Diseases , and other government agencies focused on public health which value our DNA vaccine approach to treating and preventing disease," Kim said.